Refractory Lymphoma

Showing NaN - NaN of 9

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma Trial in United States (Elimusertib)

Recruiting
  • Recurrent Alveolar Rhabdomyosarcoma
  • +7 more
  • Birmingham, Alabama
  • +28 more
Jan 26, 2023

Recurrent Lymphoma, Recurrent Malignant Solid Tumor, Recurrent Primary CNS Tumor Trial in United States (Irinotecan,

Active, not recruiting
  • Recurrent Lymphoma
  • +5 more
  • Birmingham, Alabama
  • +19 more
Oct 20, 2022

Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Tumor, Lynch Syndrome Trial in Canada,

Withdrawn
  • Constitutional Mismatch Repair Deficiency Syndrome
  • +11 more
  • Biospecimen Collection
  • +2 more
  • Palo Alto, California
  • +8 more
Sep 9, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +37 more
  • Birmingham, Alabama
  • +171 more
Aug 24, 2022

Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +49 more
  • Birmingham, Alabama
  • +1429 more
Aug 17, 2022

Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Tumor in the CNS, Recurrent Diffuse Intrinsic Pontine Glioma Trial

Active, not recruiting
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • +10 more
  • FACT Complex-targeting Curaxin CBL0137
  • Birmingham, Alabama
  • +19 more
Jun 29, 2022

Lymphoma, Relapsed Lymphoma, Refractory Lymphoma Trial in United States (fimepinostat, Rituximab, venetoclax)

Completed
  • Lymphoma
  • +10 more
  • Los Angeles, California
  • +10 more
May 5, 2021

Advanced Malignant Solid Tumor, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial in

Completed
  • Advanced Malignant Solid Neoplasm
  • +24 more
  • Oxidative Phosphorylation Inhibitor IACS-010759
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 23, 2020